脑淀粉样血管病血脑屏障渗漏的在体对比剂成像探索研究
结果显示软脑膜渗漏(沟回CSF强化)仅见于CAA患者,且与皮层表面含铁血黄素沉积(cSS)体积相关;皮层通透性表面积乘积(PS)在CAA组数值上更高但差异未达统计学意义。
要点
- 沟回CSF强化仅见于CAA患者,局灶CSF强化两组发生率相近。
- CAA患者中局灶与沟回CSF强化计数均与cSS体积相关,与脑微出血无关。
- 皮层PS在CAA组数值更高但组间差异未达统计学意义,需随访研究验证其生物标志物价值。
核心结论
- 注射钆对比剂后可在体测量CAA患者软脑膜血管的血脑屏障渗漏,结果亦提示可能存在皮层小血管渗漏。
- 软脑膜血管渗漏与cSS相关,能否作为CAA预测性生物标志物尚需随访研究确定。
研究设计与样本
- 前瞻性观察性探索研究,招募无既往脑出血的可能CAA患者与记忆门诊非CAA轻度认知障碍患者。
- 受试者接受3T脑MRI并注射钆对比剂Dotarem,评估软脑膜血管渗漏并行动态对比增强扫描量化PS。
主要发现
- 局灶CSF强化在CAA患者(7例[50%])与非CAA对照(4例[57%],p=0.98)中发生率相近。
- 沟回CSF强化仅见于CAA患者(5例[36%] vs 0例[0%])。
- CAA患者中局灶与沟回CSF强化计数与更高cSS体积相关(B=2.61,p=0.003;B=1.02,p=0.02),与CMB无关。
- 皮层PS在CAA组为5.08±4.02×10-4 min-1,非CAA对照为1.29±4.08×10-4 min-1(p=0.07),且PS与CMB计数或cSS体积无关(p>0.67)。
临床怎么用
- 对可能CAA患者可考虑用钆对比剂MRI在体评估软脑膜血脑屏障渗漏,沟回CSF强化与cSS负荷相关。
- 皮层PS组间差异未达统计学意义,暂不宜作为临床定量指标使用。
局限性
- 对照组来自记忆门诊的轻度认知障碍患者,非健康人群。
- PS组间差异仅为数值趋势(p=0.07),且缺乏随访数据验证预测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Blood-brain barrier (BBB) leakage may be an early step in the pathophysiology of cerebral amyloid angiopathy (CAA), possibly preceding hemorrhages. This exploratory study measured BBB leakage in vivo at the level of the leptomeningeal and small parenchymal vessels in patients with probable CAA. We hypothesized that BBB leakage from leptomeningeal and cortical small vessels would be higher in patients with CAA compared with controls and that leakage would be associated with hemorrhagic manifestations of CAA, that is, cortical superficial siderosis (cSS) and lobar cerebral microbleeds (CMBs). METHODS: Patients with probable CAA without previous intracerebral hemorrhage and non-CAA patients with mild cognitive impairment from the memory clinic were recruited in this prospective observational exploratory study. Participants underwent 3T brain MRI with injection of a gadolinium-based contrast agent (Dotarem). Leakage from leptomeningeal vessels was assessed on postcontrast vs precontrast T2-fluid-attenuated inversion recovery as either focal or sulcal CSF enhancements. Dynamic contrast-enhanced scans were analyzed to quantify permeability-surface area product (PS): a measure of leakage from parenchymal small vessels. RESULTS: Fourteen patients with CAA (mean age 67.7 ± 9.0 years; 57% female) and 7 non-CAA patients with mild cognitive impairment (mean age 70.1 ± 6.5 years; 29% female) were recruited. Focal CSF enhancements were observed similarly often in patients with CAA (7 [50%]) and non-CAA controls (4 [57%], p = 0.98), whereas sulcal CSF enhancements were only seen in patients with CAA (5 [36%] vs 0 [0%]). In patients with CAA, focal and sulcal CSF enhancement counts were associated with higher cSS volume (B = 2.61, p = 0.003; B = 1.02, p = 0.02), but not with CMBs. PS was numerically higher in the cortex in patients with CAA (5.08 ± 4.02 × 10-4 min-1) than in non-CAA controls (1.29 ± 4.08 × 10-4 min-1, p = 0.07), but it was not associated with CMB count or cSS volume (p > 0.67). DISCUSSION: Leakage of gadolinium-based contrast agent through the BBB can be measured in vivo in CAA from the leptomeningeal vessels, and findings point to likely leakage from cortical small vessels as well. Leakage from leptomeningeal vessels was associated with cSS. Studies with follow-up data need to determine whether these measures could serve as a predictive biomarker in CAA.
引用
- van den Brink H, Kozberg MG, Makkinejad N, et al. In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy: An Exploratory Study. Neurology. 2025. PMID: 41191838. doi:10.1212/WNL.0000000000214336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。